About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Pre-Hospital Administration of Bivalirudin More Effective Than Heparin in Reducing Mortality Risk Among Heart Attack Patients

by Kathy Jones on November 3, 2013 at 10:00 PM
Font : A-A+

 Pre-Hospital Administration of Bivalirudin More Effective Than Heparin in Reducing Mortality Risk Among Heart Attack Patients

Blood thinner bivalirudin is more effective than heparin with optional use of glycoprotein IIb/IIIa inhibitors in reducing risk of death and major bleeding complications in patients with ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) in a pre-hospital setting, a new study reveals.

Findings from the EUROMAX trial were reported today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Results of the trial were simultaneously published today in the New England Journal of Medicine.

Advertisement

The EUROMAX trial evaluated the administration of anticoagulant therapy prior to hospital admission by an emergency medical team. The trial compared a heparin-based strategy (with or without glycoprotein IIb/IIIa receptor inhibitors (GPIs) to a bivalirudin-based strategy. The primary endpoint was a composite incidence of death or non-coronary-artery-bypass-graft related protocol major bleeding at 30 days, assessed by intention to treat.

While bivalirudin has been compared to other blood thinners in hospital settings, the EUROMAX study is the first to evaluate these anticoagulant therapy options prior to hospital admission and in conjunction with newer P2Y12 inhibitors such as prasugrel and ticagrelor. The randomized, international, prospective, open-label ambulance trial enrolled 2,198 patients with STEMI and intended for primary PCI, presenting either via ambulance or to centers where PCI is not performed.
Advertisement

Patients either received bivalirudin (n=1,089) or heparin (n=1,109) at guideline-recommended doses (with or without routine or bailout GPI).

After 30 days, patients that received bivalirudin, as compared with the heparin group, experienced a significantly lower rate of death and major bleeding (5.1 percent vs. 8.4 percent, respectively). The secondary composite outcome of death, reinfarction and major bleeding at 30 days was also reduced with bivalirudin (6.7 percent in the bivalirudin group compared to 9.1 percent in the heparin group). Despite a lower rate of bleeding complications in the bivalirudin-treated patients, the risk of acute stent thrombosis was higher in the bivalirudin group compared to the heparin group (1.1 percent vs. 0.2 percent, respectively), findings that parallel those observed in the HORIZONS-AMI trial.

"The benefits of bivalirudin stemmed from a substantial reduction in major bleeding and were robust and consistent across subgroups, regardless of the adjunctive oral antiplatelet therapy or the arterial access route used for angioplasty," said lead investigator Philippe Gabriel Steg, MD. Dr. Steg is the Director of the Coronary Care Unit at the Hopital Bichat at Assistance Publique - H˘pitaux de Paris in France.

"Findings from EUROMAX provide important additional insights into the role of bivalirudin in the pre-hospital setting prior to primary PCI."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
Breast Cancer Awareness Month 2021 - It's time to RISE
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chest Pain Cardiac Catheterization Heart Attack Diet Lifestyle and Heart Disease Coronary Artery Bypass Grafting Stress and the Gender Divide Heart Attack Facts Heart Heart Attack- Lifestyle Risks Healthy Heart 

Recommended Reading
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to ......
Congestive Heart Failure
Congestive heart failure (CHF) is a condition in which the heart fails to work adequately as a pump ...
Diet from Crete for Healthy Heart
Mediterranean diets, special attention has been given to the traditional Greek Cretan diet. It ......
Heart Attack - Animation
Animation of Heart Attack symptoms. Heart attack is caused due to ischemia of the heart muscles ......
Cardiac Catheterization
Cardiac catheterization is a radiological procedure for both diagnosis and treatment of heart condit...
Chest Pain
Ask any one who has experienced intense chest pain and they will vouch for the fact that it was the ...
Coronary Artery Bypass Grafting
Coronary artery bypass grafting (CABG) or heart bypass surgery is an open heart surgery to relieve t...
Heart Attack
Heart attack is the death of the heart muscle due to loss of blood supply. Heart disease is the lead...
Stress and the Gender Divide
Stress has become entwined in the current lifestyle of a young working couple and has resulted in th...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use